A five-year review of children with neuroblastoma at Dr. Sardjito General Hospital, Yogyakarta, Indonesia

  • Sutaryo Sutaryo
  • Scolastika Dita Kristian Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada - Dr. Sardjito General Hospital, Yogyakarta
Keywords: neuroblastoma; pediatric; characteristic; overall survival; LMIC


Background Neuroblastoma is the third most common tumor in children, after leukemia and retinoblastoma. The disease presents with a wide range of symptoms.

Objective To assess the clinical profiles of children with neuroblastoma at Dr. Sardjito General Hospital from 2012-2016.

Methods A retrospective review of all children with neuroblastoma under 18 years of age in the Children’s Ward of Dr. Sardjito General Hospital, Yogyakarta from 2012-2016. Patients diagnosed and treated in other hospitals were excluded. Data were taken from the Yogyakarta Pediatric Cancer Registry (YPCR) and medical records. Outcomes were assessed by patient status: alive, died, or lost to follow-up.

Results A total of 40 subjects were included in this study. Six (15.0%) patients were diagnosed at <1 year of age, 26 (65.0%) patients at 1 to <5 years of age, 6 (15.0%) patients at 5 to <10 years of age, and 2 (5.0%) patients at ≥10 years of age. The male to female ratio was 1.5:1. Four (10.0%) patients had stage IV-S, 34 (85.0 %) patients had stage IV, and 2 (5.0 %) patients had stage II/III of the disease. Proptosis (40.0%) and abdominal mass (35.0%) were the most common chief complaints. Eight (20.0%) patients were alive at the end of observation, 15 (37.5%) died, and 17 (42.5%) were lost to follow-up. The deaths were mostly caused by sepsis.

Conclusion Most patients are  diagnosed at the age of 1 to <5 years, with a median age of 3 years. Proptosis is  the most common chief complaint. Most patients present in stage IV. Overall survival rate is very low. The high numbers of lost to follow-up should be noted.


1. Ali K, Sutaryo S, Purwanto I, Mulatsih S, Supriyadi E, Widjajanto PH, et al. Yogyakarta Pediatric Cancer Registry: an international collaborative project of University Gadjah Mada , University of Saskatchewan , and the Saskatchewan Cancer Agency. Asian Pac J Cancer Prev. 2010;11:131-6.
2. Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. The epidemiology of neuroblastoma: a review. Paediatr Perinat Epidemiol. 2009;23:125-43.
3. Silva IDS. The role of cancer registries. Geneva: World Health Organization, International Agency for Research in Cancer; 1999. p. 384-403.
4. Shinagawa T, Kitamura T, Katanoda K, Matsuda T, Ito Y, Sobue T. The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: a descriptive study. Int J Cancer. 2017;140:618-25.
5. Parkin DM, Stiller CA, Draper GJ, Bieber CA, Terracini B, Young JL. International Incidence of Childhood Cancer. In: IARC Scientific Publications No 87. Lyon: International Agency for Research on Cancer; 1998. p. 124-6.
6. Altman AJ, Quinn JJ. Management of malignant solid tumors. In: Nathan DG, Orkin SH, editors. Nathan and Oski’s hematology of infancy and childhood. 5th ed. Philadelphia: WB Saunders; 1998. p. 1381-458.
7. Laverdiére C, Liu Q, Yasui Y, Nathan PC, Gurney JG, Stovall M, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101:1131-40.
8. Ater JL. Neuroblastoma. In: Behrman RE, Jenson HB, Stanton BF, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia: WB Saunders; 2007. p. 2137-40.
9. Bordbar MR, Tashibi M, Kanfiroozi R, Haghpanah S. Epidemiological and clinical characteristics of neuroblastoma in southern iran. Iran J Ped Hematol Oncol. 2014;4:89-96.
10. Tonbary YAL, Badr M, Mansour A, et al. Clinico-epidemiology of neuroblastoma in north east Egypt?: A 5-year multicenter study. Oncol Lett. 2015;10:1054-1062. doi:10.3892/ol.2015.3335.
11. Malis J. Clinical presentation of neuroblastoma. In: Shimada H. Neuroblastoma. London: Intech Open; 2013. p:3-12. doi: http://dx.doi.org/10.5772/55921.
12. Park JR, Bagatell R, Cohn SL, Pearson AS, Villablanca JG, Berthold F, et al. Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017;35:2580-7.
13. Bansal D, Marwaha RK, Trehan A, Rao KLN, Gupta V. Profile and outcome of neuroblastoma with conventional chemotherapy in children older than one year: a 15- years experience. Indian Pediatr. 2008;45:135-9.
14. Savino PJ, Glaser JS. Opsoclonus. Pattern of regression in a child with neuroblastoma. Br J Ophthalmol. 1975;59:696-8.
15. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist. 2003;8:278-92.
16. Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasasbas P, et al. SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015;62:1305-16.
17. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer. 2001;92:2451-61.
18. Verly IR, van Kuilenburg AB, Abeling NG, Goorden SM, Flocco M, Vaz FM, et al. Catecholamines profiles at diagnosis: increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients. Eur J Cancer. 2017;72:235-43.
19. Lopci E. Neuroblastoma: from diagnosis to treatment. J Pediatr Oncol. 2015;3:38-42.
20. Cangemi G, Reggiardo G, Barco S, Barbagallo L, Conte M, D'Angelo P, et al. Prognostic value of ferritin , neuron-specific enolase , lactate dehydrogenase , and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Onco Targets Ther. 2012;5:417-23.
21. Nakazawa A, Haga C, Ohira M, Okita H, Kamijo T, Nakagawara A. Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma. Cancer Sci. 2015;106:766-71.
22. Strenger V, Kerbl R, Dornbusch HJ, Ladenstein R, Ambros PF, Ambros IM, et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer. 2007;48:504-9.
23. Iehara T, Hosoi H, Akazawa K, et al. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening. Br J Cancer. 2006;94:1510-1515.
24. Trout AT, Weiss BD, Gelfand MJ. MIBG in Neuroblastoma Diagnostic Imaging and Therapy. Radiographics. 2016;36:258-278.
25. Salazar BM, Balczewski EA, Ung CY, Zhu S. Neuroblastoma , a Paradigm for Big Data Science in Pediatric Oncology. Int J Mol Sci. 2017;18:1-27.
26. Peinemann F, Kahangire DA, van Dalen EC, Berthold F. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma ( Review ). Cochrane Database Syst Rev. 2015;:1-50.
27. Shuster JJ, McWilliams NB, Castleberry R, Nitchke R, Smith EI, Alshuler G. Serum lactate dehydrogenase in childhood neuroblastoma. Am J Clin Oncol. 1992;15:295-303.
28. Cangemi G, Reggiardo G, Barco S, et al. Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Onco Targets. 2012;5:417-423.
29. Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013;3:1-22.
30. Bown N, Northern T. Reviews Neuroblastoma tumour genetics?: clinical and biological aspects. J Clin Pathol. 2001;54:897-910.
31. Nassin ML, Nicolaou EV, Hecktman HM, Cohen CW, Cohn SL, Cunningham JM, et al. Immune system profiling following autologous stem cell transplant for high-risk neuroblastoma reveals poor immune reconstitution at the start of immunotherapy that predicts disease-free survival. Blood, 128(22), 2251. Accessed May 20, 2019. Available from http://www.bloodjournal.org/content/128/22/2251.
32. Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, et al. Busulphan and melphalan versus carboplatin, etoposide, and melphalan as high-dose therapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18:500-14.
33. Spix C, Aareleid T, Stiller C, Magnani C, Kaatsch P, Michaelis J. Survival of children with neuroblastoma: time trends and regional differences in Europe, 1978-1992. Eur J Cancer. 2001;37:722-9.
34. Steliarova-Foucher E, Stiller C, Kaatsch P, Berrino F, Coebergh JW, Lacour B, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCIS project): an epidemiologial study. Lancet. 2004;364:2097-105.
35. Mulatsih S, Sutaryo, Ali K, Purwanto I. A five year review of children with neuroblastoma at Dr. Sardjito Hospital, Yogyakarta, Indonesia:1999-2004. BKM. 2005;XXI:55-58.
How to Cite
Sutaryo S, Kristian S. A five-year review of children with neuroblastoma at Dr. Sardjito General Hospital, Yogyakarta, Indonesia. PI [Internet]. 26Jun.2019 [cited 21Jun.2024];59(3):157-3. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2145
Pediatric Hemato-Oncology
Received 2019-03-12
Accepted 2019-06-20
Published 2019-06-26